Epileptic Seizures in Alzheimer’s Disease: What Are the Implications of SANAD II?

Article type: Article Commentary

Authors: Larner, Andrew J.^{; *} | Marson, Anthony G.

Affiliations: Walton Centre for Neurology and Neurosurgery, Liverpool, UK

Correspondence: [*] Correspondence to: Andrew J. Larner, Cognitive Function Clinic, Walton Centre for Neurology and Neurosurgery, Liverpool, L9 7LJ, UK. E-mail: a.larner@thewaltoncentre.nhs.uk.

Abstract: Epileptic seizures are increasingly recognized as part of the clinical phenotype of patients with Alzheimer’s disease (AD). However, the evidence base on which to make treatment decisions for such patients is slim, there being no clear recommendation based on systematic review of the few existing studies of anti-seizure drugs in AD patients. Here the authors examine the potential implications for the treatment of seizures in AD of the results of the recently published SANAD II pragmatic study, which examined the effectiveness of levetiracetam, zonisamide, or lamotrigine in newly diagnosed focal epilepsy, and of valproate and levetiracetam in generalized and unclassifiable epilepsy.

Keywords: Alzheimer’s disease, epilepsy, seizures, treatment

DOI: 10.3233/JAD-215154

Journal: Journal of Alzheimer's Disease, vol. 85, no. 2, pp. 527-529, 2022